Sonus EchoGen
Executive Summary
FDA has again requested additional data to support NDA for ultrasound contrast agent. In August, Sonus responded to an FDA "not approvable" letter, but has now received notification that the amendment is not considered complete. Sonus is in discussions with FDA and "believes it will be able to provide all of the information requested by the FDA, but that a delay of final FDA action will result"